ORPHA:158003
Xanthoma disseminatum
Also known as: Montgomery syndrome
Publications
326
61.1th percentile
Trials
0
Interventional, condition-specific
Researchers
890
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, systemic disease characterized by normolipidemic mucocutaneous xanthomatosis with histiocytic cells proliferation and secondary deposition of lipid in the dermis. Clinically, multiple, grouped, coalescent, yellowish red to brown papulonodular lesions in the skin and mucous membranes are present. Less often internal organs are affected, in particular pituitary gland and/or hypothalamus. Patients present with characteristic mucocutaneous lesions, diabetes insipidus, dysphagia, dyspnea, hoarseness of voice, and blurred vision.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015535
- UMLS:C0043322
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
326 matched papers (131 in last 10 years) Source
- Phenotype characterisedPresent
6 HPO annotations (e.g. Abnormal lip morphology; Abnormal bronchus morphology; Diabetes insipidus) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
6
Associated phenotypes · MONDO:0015535
- Abnormal lip morphology
- Abnormal bronchus morphology
- Diabetes insipidus
- Osteolysis
- Abnormality of the pharynx
Showing 5 of 6 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
326
326 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
326 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
131 in the last 10 years · high confidence · 61.1th percentile (publications denominator)
Phrase hits: 326 · MeSH hits: 0
Who's working on it?
890
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Emile JF5 papers · 2026
Research Unit EA4340, Versailles University, Paris-Saclay University, Boulogne, France; Pathology Department, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France;
Papers in Europe PMC - 02Li J5 papers · 2026
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: lijun35@hotmail.com.
Papers in Europe PMC - 03
- 04Zelger B4 papers · 2019
Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria.
Papers in Europe PMC - 05Zhao Y4 papers · 2025
Department of Clinical Medicine, Jining Medical University, Jining, Shandong, P.R. China.
Papers in Europe PMC - 06Allen CE3 papers · 2025
Texas Children's Hospital Cancer and Hematology Center, Houston, Texas, USA.
Papers in Europe PMC - 07
- 08Chen H3 papers · 2026
Department of Dermatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Papers in Europe PMC - 09Das A3 papers · 2020
Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India.
Papers in Europe PMC - 10Diamond EL3 papers · 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY;
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 18 · after dedupe 18 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 18 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (18)
- isrctn·ISRCTN17178652·Recruiting·Assessing the effectiveness of lithium plus quetiapine compared to lithium alone or quetiapine alone for treatment of adults with bipolar disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73588250·No longer recruiting·The purpose of the trial is to test the safety, tolerability and efficacy of the drug tildacerfont, that is being developed for the treatment of major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31103960·No longer recruiting·A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12904794·No longer recruiting·A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36202964·No longer recruiting·Clinical study to assess the efficacy and safety of Silexan in patients with depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72151939·No longer recruiting·Pramipexole trial for bipolar depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17937049·No longer recruiting·Feasibility and acceptability of transcranial stimulation in obsessive-compulsive symptoms
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10584863·No longer recruiting·Psilocybin vs escitalopram for depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16387615·No longer recruiting·Lithium versus quetiapine in treatment resistant depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65727743·No longer recruiting·30-year follow-up of personality and clinical status of patients with anxiety and depression in the Nottingham Study of Neurotic Disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN07706836·No longer recruiting·A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination in the management of obsessive compulsive disorder.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37364372·No longer recruiting·A trial comparing the effectiveness of Assertive Community Treatment enhanced with evidence based interventions with standard Assertive Community Treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31767087·No longer recruiting·A high-intensity functional exercise program for older people with dementia and living in residential care facilities (The Umeå Dementia and Exercise Study – The UMDEX Study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46241817·No longer recruiting·The effects of a 6-month exercise program on mental and physical health and brain volumes in patients with schizophrenia and matched healthy controls
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97049967·No longer recruiting·Phase 3 long-term safety, tolerability and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN02658871·No longer recruiting·Secondary PREVENTion of schizophrenia: a randomised controlled trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33128015·No longer recruiting·Effects of selective serotonin re-uptake inhibition on MOrbidity, mOrtality and mood in Depressed Heart Failure patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97160532·No longer recruiting·SMRI-02T-162A: double blind placebo controlled trial of a protein kinase C inhibitor: tamoxifen citrate in treatment of acute mania
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Xanthoma disseminatum — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Xanthoma disseminatum" OR "Montgomery syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Xanthoma disseminatum" OR "Montgomery syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:04:39.364Z
